WO2000063426A3 - Compound screening methods - Google Patents

Compound screening methods Download PDF

Info

Publication number
WO2000063426A3
WO2000063426A3 PCT/IB2000/000558 IB0000558W WO0063426A3 WO 2000063426 A3 WO2000063426 A3 WO 2000063426A3 IB 0000558 W IB0000558 W IB 0000558W WO 0063426 A3 WO0063426 A3 WO 0063426A3
Authority
WO
WIPO (PCT)
Prior art keywords
screening methods
compound screening
sarco
serca
elegans
Prior art date
Application number
PCT/IB2000/000558
Other languages
French (fr)
Other versions
WO2000063426A2 (en
Inventor
Richard Zwaal
Jose Groenen
Thierry Bogaert
Original Assignee
Devgen Nv
Richard Zwaal
Jose Groenen
Thierry Bogaert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9908670.4A external-priority patent/GB9908670D0/en
Priority claimed from GBGB9912736.7A external-priority patent/GB9912736D0/en
Application filed by Devgen Nv, Richard Zwaal, Jose Groenen, Thierry Bogaert filed Critical Devgen Nv
Priority to AU39847/00A priority Critical patent/AU3984700A/en
Priority to EP00919102A priority patent/EP1171628A2/en
Priority to JP2000612503A priority patent/JP2002541859A/en
Priority to CA002369478A priority patent/CA2369478A1/en
Publication of WO2000063426A2 publication Critical patent/WO2000063426A2/en
Publication of WO2000063426A3 publication Critical patent/WO2000063426A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
    • A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43526—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms
    • G01N2333/4353—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes
    • G01N2333/43534—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides methods of screening for compounds which affect the activity of a physiologically important calcium pump, the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA), using the nematode worm C. elegans.
PCT/IB2000/000558 1999-04-15 2000-04-14 Compound screening methods WO2000063426A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU39847/00A AU3984700A (en) 1999-04-15 2000-04-14 Compound screening methods
EP00919102A EP1171628A2 (en) 1999-04-15 2000-04-14 Compound screening methods
JP2000612503A JP2002541859A (en) 1999-04-15 2000-04-14 Compound screening method
CA002369478A CA2369478A1 (en) 1999-04-15 2000-04-14 Compound screening methods

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US12959699P 1999-04-15 1999-04-15
US60/129,596 1999-04-15
GB9908670.4 1999-04-15
GBGB9908670.4A GB9908670D0 (en) 1999-04-15 1999-04-15 Compound screening method
GB9912736.7 1999-06-01
GBGB9912736.7A GB9912736D0 (en) 1999-06-01 1999-06-01 Compound screening methods

Publications (2)

Publication Number Publication Date
WO2000063426A2 WO2000063426A2 (en) 2000-10-26
WO2000063426A3 true WO2000063426A3 (en) 2001-02-08

Family

ID=27269699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/000558 WO2000063426A2 (en) 1999-04-15 2000-04-14 Compound screening methods

Country Status (7)

Country Link
EP (1) EP1171628A2 (en)
JP (1) JP2002541859A (en)
AU (1) AU3984700A (en)
CA (1) CA2369478A1 (en)
GB (1) GB2349217B (en)
HK (1) HK1029376A1 (en)
WO (1) WO2000063426A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2359627B (en) * 1999-04-15 2002-01-23 Devgen Nv Compound screening method
AU2002218457A1 (en) * 2000-10-18 2002-04-29 Devgen N.V. Methods for identifying pesticidal compounds
JP2006265102A (en) * 2003-05-08 2006-10-05 Taisho Pharmaceut Co Ltd METHOD FOR CONTROLLING APOPTOSIS DERIVED FROM TGFbeta
JP5232785B2 (en) * 2006-09-18 2013-07-10 ユーニヴァーサティ、アヴ、ノース、テクサス Multi-network neuronal analysis platform with parallel recording capability
WO2012168474A1 (en) * 2011-06-10 2012-12-13 Monell Chemical Senses Center Novel methods
EP2775302A1 (en) * 2013-03-08 2014-09-10 Assistance Publique - Hôpitaux de Paris Compound-carrier systems for assays in nematodes
CN114794029B (en) * 2022-06-09 2023-02-28 上海大学 Method for counting number of embryos developed in uterus of caenorhabditis elegans

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028886A1 (en) * 1993-06-03 1994-12-22 The University Of Sydney Use of natural products and related synthetic compounds for the treatment of cardiovascular disease
WO1998013518A1 (en) * 1996-09-26 1998-04-02 Smithkline Beecham Laboratoires Pharmaceutiques Process for detecting modulators of myocardial relaxation
WO1998051351A1 (en) * 1997-05-15 1998-11-19 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
WO1998053856A1 (en) * 1997-05-29 1998-12-03 The General Hospital Corporation Methods for the detection, treatment, and prevention of neurodegeneration
WO1999004636A1 (en) * 1997-07-22 1999-02-04 The General Hospital Corporation Evaluation of, delivery of, and use of agents to treat heart disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028886A1 (en) * 1993-06-03 1994-12-22 The University Of Sydney Use of natural products and related synthetic compounds for the treatment of cardiovascular disease
WO1998013518A1 (en) * 1996-09-26 1998-04-02 Smithkline Beecham Laboratoires Pharmaceutiques Process for detecting modulators of myocardial relaxation
WO1998051351A1 (en) * 1997-05-15 1998-11-19 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
WO1998053856A1 (en) * 1997-05-29 1998-12-03 The General Hospital Corporation Methods for the detection, treatment, and prevention of neurodegeneration
WO1999004636A1 (en) * 1997-07-22 1999-02-04 The General Hospital Corporation Evaluation of, delivery of, and use of agents to treat heart disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROUFOGALIS BASIL D; LI QIAN; TRAN VAN H; KABLE ELEANOR P W; DUKE COLIN C: "Investigation of plant-derived phenolic compounds as plasma membrane Ca2+-ATPase inhibitors with potential cardiovascular activity", DRUG DEVELOPMENT RESEARCH, vol. 46, March 1999 (1999-03-01) - April 1999 (1999-04-01), pages 235 - 249, XP000956277 *
WOLOSKER H; PACHECO A G F; DE MEIS L: "LOCAL ANESTHETICS INDUCE FAST CALCIUM EFFLUX THROUGH A NONENERGIZED STATE OF THE SARCOPLASMIC RETICULUM CALCIUM ATPASE", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 9, 25 March 1992 (1992-03-25), pages 5785 - 5789, XP002151174 *

Also Published As

Publication number Publication date
GB2349217B (en) 2001-04-04
GB0009363D0 (en) 2000-05-31
AU3984700A (en) 2000-11-02
JP2002541859A (en) 2002-12-10
GB2349217A (en) 2000-10-25
CA2369478A1 (en) 2000-10-26
HK1029376A1 (en) 2001-03-30
EP1171628A2 (en) 2002-01-16
WO2000063426A2 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
AP1830A (en) Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same.
MX255195B (en) Fungicidal mixture containing arylamidine derivatives.
HK1039487A1 (en) Process for the synthesis of azetidinones.
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
AU2002241563A1 (en) Improved deflection members for tissue production
ZA200004379B (en) Production of natural flavors by laccase.
EP1568380A4 (en) Preventive or remedy for diseases caused by hyperglycemia
WO2000063426A3 (en) Compound screening methods
WO2000063425A3 (en) Compound assay using nematodes
HK1050904A1 (en) Process for rapid solution synthesis of peptides.
WO2000063427A3 (en) Compound screening method
ZA200403568B (en) Treatment of a wide range of titanium compounds.
WO2002100895A3 (en) Antimicrobially active peptide
MXPA03000914A (en) Synthesis of (r.
DE69917005D1 (en) SUBSTITUTED PYRROLOBENZIMIDAZOLE DERIVATIVES FOR ANTI-INFLAMMATION
GB9918429D0 (en) Organic compounds
ZA200000312B (en) Process for the preparation of 1,2-dichloroethane from oxychlorination.
MXPA03008211A (en) Predispersions, process for their preparation, compositions therefor, process for the preparation of such compositions.
IT1303265B1 (en) DISC OR SEMI-DISC FOR SINGLE CYLINDER CIRCULAR MACHINES FOR KNITWEAR OR FOOTWEAR, PARTICULARLY FOR THE PRODUCTION OF
HK1027110A1 (en) Production of avermectin compounds.
MXPA03002926A (en) Process for the synthesis of 2,2,6,6-tetramethyl-4-oxopiperidine.
MXPA02003042A (en) Process for preventing formation of scale.
GB9811962D0 (en) Vertebrate homologue of UNC-53 protein of C.elegans
ZA200205835B (en) Compounds useful for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor.
EP1406614A4 (en) Carvedilol polymorph

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2369478

Country of ref document: CA

Ref country code: CA

Ref document number: 2369478

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 612503

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000919102

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000919102

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000919102

Country of ref document: EP